Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than consolidated financial performance.
Material Changes
On January 10, 2011, Mr. A P Witty acquired a total of 636 Ordinary shares under the dividend re-investment element of the Plan. This consisted of 318 shares from a personal contribution and 318 shares from the Company contribution. The transaction occurred at a price of £12.52 per share following the re-investment of dividends paid on January 6, 2011.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that vest following the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting schedule and conditions for the 2009 Deferred Annual Bonus Plan.
- Confirm the total number of shares held by Mr. A P Witty post-transaction.
- Review the dividend payment date of January 6, 2011, to validate the re-investment timing.